コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 stitis (AC) is the most common biliary stone disease complication.
2 healthcare will contribute to acute chronic disease complications.
3 ost valid endpoint used to determine risk of disease complications.
4 rophil GM-CSF signaling in cell function and disease complications.
5 fective, modify or change therapy, and avoid disease complications.
6 atients, 78 (9%) of whom experienced Crohn's disease complications.
7 herence is common and results in preventable disease complications.
8 of disease predisposition or development of disease complications.
9 clinical problem that mediates most vascular disease complications.
10 ients susceptible to disease reactivation or disease complications.
11 rly posttransplant to prevent cardiovascular disease complications.
12 rol glycaemia with insulin therapy to reduce disease complications.
13 and those pathological processes that cause disease complications.
14 orrelates with disease activity and predicts disease complications.
15 to T effector cells, and a high frequency of disease complications.
16 ities and contributes to and predicts distal disease complications.
17 f the affected relatives experienced adverse disease complications.
18 ategy in treating CKD and its cardiovascular disease complications.
19 ion with TWASs for stratification of risk of disease complications.
20 perpetuating tissue fibrosis and longer-term disease complications.
21 mation, and tissue injury that contribute to disease complications.
22 physiologic oxygen values thereby mitigating disease complications.
23 adulthood, but many develop a high burden of disease complications.
24 atient's treatment plan preventing potential disease complications.
25 enomena to the development of non-infectious disease complications.
26 ar, coronary artery, and peripheral arterial diseases) complications.
28 disease, which represents an underrecognized disease complication and contributes to excess morbidity
29 because of the frequency of this spectrum of disease complication and its potential for severe VA imp
30 es suggested that LOX upregulation indicates disease complications and fibrostenotic conditions in pa
31 y for adult WAS patients with severe chronic disease complications and for whom an allogeneic procedu
32 ion of fetal hemoglobin (HbF) can ameliorate disease complications and has been intently pursued.
33 normalities are more severe in patients with disease complications and in those with a greater degree
35 on, individuals with IS had a higher risk of disease complications and poor outcomes than individuals
38 k for advanced heart failure symptoms, other disease complications, and HCM-related mortality, and la
39 critical for maintaining health, minimizing disease complications, and improving quality of life.
40 g the systemic iron concentration to relieve disease complications, and our data suggest that iron-in
42 tics with emphasis on specific locations and disease complications, and the differential diagnosis co
43 tive TDM, to assess the effects on long-term disease complications, and to evaluate the cost-effectiv
45 ains or strains more likely to cause serious disease complications are causally associated with speci
46 of patients with PV or ET is near-normal and disease complications are effectively (and safely) manag
47 natural course of PNH, reducing symptoms and disease complications as well as improving survival to a
48 rically has been characterized as a decisive disease complication associated with substantial risk fo
49 nsidered a particularly grim and unfavorable disease complication, associated with substantial morbid
50 rapies, with the goal of not only addressing disease complications but also potentially modifying dis
53 African Americans with SSc have more severe disease complications compared to Caucasians with SSc, a
54 sured the proportion who experienced a liver disease complication (decompensated cirrhosis, hepatocel
55 h moderate-to-severe asthma continue to have disease complications despite the receipt of standard-of
56 18 biochemical tests, complete blood counts, disease complications, duration of hospital admission, a
57 mpered our abilities to recognize individual disease complications, especially in the rarer forms.
58 ricular apical aneurysms experienced adverse disease complications (event rate, 10.5%/y), including s
60 es was defined by self-report of diabetes or disease complication, fasting glucose level of 6.9 mmol/
61 -causing genetic variants and are at risk of disease complications have incomplete and/or late-onset
63 s is incomplete without the consideration of disease complications in both the central and peripheral
64 with incidence of CD and the development of disease complications in children with CD up to 5 years
65 on-MPN driver mutations (NDM) on the risk of disease complications in HC-RES/INT ET patients is unkno
66 hether luspatercept could improve anemia and disease complications in patients with beta-thalassemia.
69 e also been meager in terms of treatment for disease complications, including anemia, splenomegaly, a
70 resence and extent of several characteristic disease complications, including basilar impression, spi
72 has been prominently associated with adverse disease complications, including sudden death or heart f
74 ised patients with influenza had more severe disease/complications, longer viral shedding, and more a
75 he morbidity from SCA, but prevention of all disease complications may require minimizing the fractio
76 een fully validated as surrogates of risk of disease complications; mucosal healing is the most valid
78 strointestinal bleeding, small bowel Crohn's disease, complications of coeliac disease and surveillan
79 in the population of adults living with the disease, complications of cystic fibrosis are becoming i
80 or limb malperfusion attributable to aortic disease, complications of reinterventions, or aortic rup
81 psy remains the gold standard for staging of disease, complications of this procedure and other well-
82 hanisms of nerve injury including infectious diseases, complication of medical diseases, and mechanic
83 odies and has limited efficacy in preventing disease complications or mortality among hospitalized pa
84 CD (children who have not yet suffered overt disease complications or only had mild problems) is cont
85 is one of the most effective ways to prevent disease complications, reduce patient mortality, and cur
86 ly treatment on quality of life, disability, disease complications, risk of neoplastic lesions, and m
87 of survival appear to be those related to RA disease complications, specifically, extraarticular mani
88 ion of immune and nonimmune cells leading to disease complications such as aberrant tissue repair and
90 Patients may also experience other severe disease complications, such as hospitalization and surge
91 ntral role in the development of more severe disease complications, such as mitten deformities of han
92 th cystic fibrosis an understanding of those disease complications that will require surgical consult
93 thors describe the signs and symptoms of the disease, complications that arise, and expected outcome